The future of CTCL therapy

2 Bekeken
administrator
administrator
08/09/23

Julia Jane Scarisbrick, MBChB, FRCP, MD, University Hospital Birmingham, Birmingham, UK, shares her views on the future of cutaneous T-cell lymphoma (CTCL) therapy, highlighting the unmet need for more efficacious therapies and to determine the optimal sequencing of therapies. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.

  • categorie

Laat meer zien

0 Comments Sorteer op

Geen reacties gevonden

Facebook Reacties

Volgende